Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete - Seite 2
According to the CDC, "In 2019, for example, CDC estimated that ‘the economic cost of injury was $4.2 trillion, including $327 billion in medical care, $69 billion in work loss, and $3.8 trillion in value of statistical life and quality of life losses"[1]. The potential market for a product that proactively treats TBI through the timely suppression of specific excess neurotransmitters and inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need, let alone in a timely manner. If the MSU test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous potential economically and from a humanitarian standpoint.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire
Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of
Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals
with a genuine passion and drive.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC
Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or
utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and
assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of
management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could
differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2023, Halberd Corporation
[1] https://www.ncbi.nlm.nih.gov/books/NBK580076/#_pz54-2_
Lesen Sie auch
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/756513/Halberd-Initial-Preclinical-Testing- ...
The Halberd Stock at the time of publication of the news with a raise of 0,00 % to 0,009USD on Nasdaq OTC stock exchange (23. Mai 2023, 02:10 Uhr).